<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Perioperative management of oral direct thrombin inhibitors and factor Xa inhibitors</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Perioperative management of oral direct thrombin inhibitors and factor Xa inhibitors</h1>
<div class="graphic"><div class="figure"><div class="ttl">Perioperative management of oral direct thrombin inhibitors and factor Xa inhibitors</div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="16%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1" rowspan="2">Anticoagulant</td> <td class="subtitle1" rowspan="2">Kidney function and dose</td> <td class="subtitle1" colspan="2"> <p>Interval between last dose and procedure</p> NOTE: No anticoagulant is administered the day of the procedure</td> <td class="subtitle1" colspan="2">Resumption after procedure</td> </tr> <tr class="divider_bottom"> <td class="subtitle2">High bleeding risk</td> <td class="subtitle2">Low bleeding risk</td> <td class="subtitle2">High bleeding risk</td> <td class="subtitle2">Low bleeding risk</td> </tr> <tr> <td class="divider_bottom" rowspan="2">Dabigatran</td> <td> <p>CrCl &gt;50 mL/minute</p> Dose 150 mg twice daily</td> <td>Give last dose 3 days before procedure (ie, skip 4 doses on the 2 days before the procedure)</td> <td>Give last dose 2 days before procedure (ie, skip 2 doses on the day before the procedure)</td> <td class="align_middle centered" rowspan="8">Resume 48 to 72 hours after surgery (ie, postoperative day 2 to 3)</td> <td class="align_middle centered" rowspan="8">Resume 24 hours after surgery (ie, postoperative day 1)</td> </tr> <tr> <td class="divider_bottom"> <p>CrCl 30 to 50 mL/minute</p> Dose 150 mg twice daily</td> <td class="divider_bottom">Give last dose 5 days before procedure (ie, skip 8 doses on the 4 days before the procedure)</td> <td class="divider_bottom">Give last dose 3 days before procedure (ie, skip 4 doses on the 2 days before the procedure)</td> </tr> <tr> <td class="divider_bottom" rowspan="2">Rivaroxaban</td> <td> <p>CrCl &gt;50 mL/minute</p> Dose 20 mg once daily</td> <td class="divider_bottom" rowspan="2">Give last dose 3 days before procedure (ie, skip 2 doses on the 2 days before the procedure)</td> <td class="divider_bottom" rowspan="2">Give last dose 2 days before procedure (ie, skip 1 dose on the day before the procedure)</td> </tr> <tr> <td class="divider_bottom"> <p>CrCl 30 to 50 mL/minute</p> Dose 15 mg once daily</td> </tr> <tr> <td class="divider_bottom" rowspan="2">Apixaban</td> <td> <p>CrCl &gt;50 mL/minute</p> Dose 5 mg twice daily</td> <td class="divider_bottom" rowspan="2">Give last dose 3 days before procedure (ie, skip 4 doses on the 2 days before the procedure)</td> <td class="divider_bottom" rowspan="2">Give last dose 2 days before procedure (ie, skip 2 doses on the day before the procedure)</td> </tr> <tr class="divider_bottom"> <td> <p>CrCl ≤50 mL/minute</p> Dose 2.5 mg twice daily</td> </tr> <tr> <td rowspan="2">Edoxaban</td> <td> <p>CrCl 51 to 95 mL/minute</p> Dose 60 mg once daily</td> <td rowspan="2">Give the last dose 3 days before the procedure (ie, skip 2 doses on the 2 days before the procedure)</td> <td rowspan="2">Give the last dose 2 days before the procedure (ie, skip 2 dose on the day before the procedure)</td> </tr> <tr> <td> <p>CrCl ≤50 mL/minute*</p> Dose 30 mg once daily</td> </tr> </tbody></table></div><div class="graphic_lgnd">Bleeding risk is determined primarily by the type of surgery; patient comorbidities may also play a role. In patients undergoing neuraxial anesthesia or a very high bleeding risk procedure, a longer period of interruption may be warranted. In many low bleeding risk procedures, the anticoagulant does not need to be interrupted. Bridging anticoagulation may be appropriate preoperatively in patients with a very high thromboembolic risk who require more prolonged interruption of the anticoagulant (eg, for renal insufficiency) and/or postoperatively in patients who are unable to resume the anticoagulant (eg, unable to take oral medication due to intestinal ileus). Refer to the UpToDate topics on perioperative management of patients receiving anticoagulants for further details.</div><div class="graphic_footnotes"><p>CrCl: creatinine clearance.</p>
* Product information varies in different countries regarding a lower limit of CrCl below which the drug should not be used. As an example, product information in the United States specifies avoiding use with CrCl &lt;15 mL/minute.</div><div id="graphicVersion">Graphic 93260 Version 12.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
